Search results
Results from the WOW.Com Content Network
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase;
chronic lymphocytic leukemia: Ceritinib [1] Novartis Pharmaceuticals: ALK-positive metastatic non-small cell lung cancer: Idelalisib [1] Gilead Sciences: relapsed chronic lymphocytic leukemia: Ibrutinib [1] Pharmacyclics: chronic lymphocytic leukemia (with 17p deletion Eltrombopag [1] Novartis Pharmaceuticals: aplastic anemia: Pembrolizumab [1 ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The drug or other substance has a currently [1] accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence. The complete list of Schedule III substances is as follows.
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. [2] For CLL it is a preferred treatment. [3] It is given by mouth. [3] Common side effects include bone marrow suppression. [3]
Obecabtagene autoleucel (Aucatzyl): treatment of acute lymphoblastic leukemia [14] [15] Onasemnogene abeparvovec (Zolgensma): AAV-based treatment for spinal muscular atrophy [16] Strimvelis: treatment for adenosine deaminase deficiency (ADA-SCID) Talimogene laherparepvec (Imlygic): treatment for melanoma in patients who have recurring skin ...
According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion. [21]: 3, 7–8 Competition as well as potential for combination is expected from other drugs such as ibrutinib and idelalisib, both of which were also approved in 2014 to treat CLL. [21]: 7–8 [22]
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. [8] [9] In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. [8] [9] In patients with CLL, B cell lymphocytes can begin to collect in their blood, spleen, lymph nodes, and bone marrow.